Microbiome research company Clinical Microbiomics has acquired MS-Omics, a leading provider based in Denmark.
With this acquisition, Clinical Microbiomics hopes to further advance its systems biology platform and help researchers worldwide understand the microbiome and how to impact health and disease.
Anders Grøn, CEO at Clinical Microbiomics, commented: “There is an unmet need in the microbiome field for better solutions to integrate microbiome and metabolome data. This demands a truly interdisciplinary approach – one that is made possible through this acquisition. We’re excited to engage with our network of researchers around the world to bring the new platform and services to work.”
The microbiome is a major source of variation in the human metabolome. By utilising advanced bioinformatics and systems biology to integrate the two disciplines, Clinical Microbiomics aims to pave the way for new innovations.
Morten Danielsen, CEO at MS-Omics, added: “This transaction is a big milestone for our companies. It is a result of a strategic dialogue where it became clear that together we would be uniquely positioned to address microbiome research questions across the field.”
Earlier this month, Clinical Microbiomics received a €10 million investment from Seventure Partners’ “Health for Life Capital™ II” fund.